Endometriosis Awareness: More than a monthly reminder
- Ronell Klingman
- Mar 18, 2024
- 2 min read
Updated: Oct 17, 2024
DID YOU KNOW?
Endometriosis impacts almost 10% of reproductive-age women, leading to considerable pain and infertility. Alarmingly, a recent study by Endometriosis UK found that obtaining an endometriosis diagnosis in the UK averages eight years and 10 months. This delay often stems from the challenge in recognizing the disease based on nonspecific symptoms, particularly during its initial phases, highlighting the need for increased awareness.
Globally, around 200 million women are diagnosed with endometriosis. Diagnosis relies on laparoscopic examination which is typically reserved for later stages of the disease due to associated risks and patient reluctance, making early detection challenging.
PROMISING ADVANCEMENTS
Exciting advancements are on the horizon. Serum microRNAs show promise as non-invasive indicators to detect endometriosis earlier. New treatments, such as specific antibodies targeting endometriotic cells while preserving hormonal balance, represent significant progress. Studies report reduced lactate production in pelvic wall cells following dichloroacetate treatment, a crucial discovery given the link between lactate levels and endometriosis development. This novel medication offers hope as a non-hormonal, non-surgical treatment.
The Norfolk and Norwich University Hospital (NNUH) is conducting a non-hormonal drug trial for endometriosis. This Phase II trial evaluates the safety and effectiveness of AMY109, an antibody to reduce inflammation and ease endometriosis symptoms. AMY109 targets interleukin-8, a protein implicated in the inflammatory response to endometriosis. Researchers anticipate that it not only alleviates inflammation but also may reduce existing scarring. Its non-hormonal nature suggests it may be a viable option for people unable to use contraceptives.
CHALLENGES TO BE OVERCOME
Despite advancements, challenges persist in managing endometriosis. Inadequate awareness and understanding among healthcare providers often result in misdiagnosis and delayed treatment. In the Endometriosis UK study, approximately 78% of diagnosed individuals reported doctors dismissing their concerns as "making a fuss about nothing" or similar remarks. The normalization of women's pain and a biomedical perspective exacerbate challenges.
Raising awareness, supporting research, and improving patient-provider communication can ease the burden of endometriosis and improve women's lives. Contact Integremed to explore how our expertise can assist your brand in marketing treatment options for women affected by this often-overlooked condition.
Learn more:
doi: 10.1073/pnas.1916144116
